Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Cheryl Galt who wrote (27289)	1/7/1999 5:20:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Cheryl, The LLY/LGND deal includes a research program on treating cancer (almost certainly breast cancer) with SERM (like Evista) and Rexinoid (like Targretin, LGD1268, and LGD1324) combos. It's not clear (at least to me) if it only targets second generation compounds (LLY has a potent 2nd generation SERM and LGND has at least LGD1269 and LGD1324 as second generation rexinoids) nor is the partnership arrangement of share profits from profits from such 2nd generation compounds for cancer treatment (and prevention?) applications.